{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001329","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.150474+00:00","generated_at":"2026-06-05T22:37:53.722726+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tactile Medical Q4 net income up 77% to $8.2M; FY revenue $274.4M (+11%); introduces FY24 outlook $300-305M","bullets":["Q4 2023 revenue $77.7M (+5% YoY); net income $8.2M (+77%); diluted EPS $0.35 vs $0.23.","FY2023 revenue $274.4M (+11% YoY); net income $28.5M (vs net loss $17.9M in 2022); diluted EPS $1.23.","FY2023 adjusted EBITDA $29.7M (+62% YoY); operating cash flow $35.9M (+$30.6M); debt down to $29.3M.","FY2024 revenue guidance $300M-$305M (9-11% growth); cash $61.0M; completed $16.8M revolver retirement.","Over 77,000 patients treated; introduced Entre Plus and Flexitouch ComfortEase upper extremity garments."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001329","json":"https://secwatch.observer/filing/0001558370-24-001329.json","markdown":"https://secwatch.observer/filing/0001558370-24-001329.md","text":"https://secwatch.observer/filing/0001558370-24-001329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837024001329/0001558370-24-001329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837024001329/tcmd-20240220x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:37:53.722726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02cfd59711b0815baee99319b527e18cd9bc01b7","claim":"TACTILE SYSTEMS TECHNOLOGY INC reported the fourth quarter and full year ended December 31, 2023 results: revenue $77.7 million, net income $8.2 million, or $0.35 per diluted share, EPS $0.35 per diluted share. Guidance initiated.","evidence_excerpt":", today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: ● Total revenue increased 5% over prior year to $77.7 million ● Net income increased 77% over prior year to $8.2 million ● Adjusted EBITDA increased 27% over prior year to $15.4 million ● Retired $16.8 million revolving line of credit and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1027838/000155837024001329/0001558370-24-001329-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$77.7 million"},{"label":"Net income","value":"$8.2 million, or $0.35 per diluted share"},{"label":"EPS","value":"$0.35 per diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}